external-file_edited (1)_edited_edited_edited_edited.png

Hello.

Welcome to BioFocus.
Explore the latest updates from the life science industry.

Featured Articles.

BIOTECH

Houdini Bio: tackling the gene-silencing barrier in genetic medicines

BIOTECH

Oxford and 2U Launch New Programme in AI-Driven Drug Discovery

PHARMA

How Automation is Accelerating Drug Discovery Timelines

BIOPROCESSING

Bio-Rad Expands Foresight Pro Chromatography Columns for Biomanufacturing

PHARMA

EyePoint’s DURAVYU misses first Phase 3 endpoint in wet AMD, putting focus on second trial

HEALTH

A New Device Could Improve How Progesterone is Delivered in Early Pregnancy

BIOTECH

Shift Bioscience says better benchmarking could make AI “virtual cells” more useful for finding ageing drug targets

PHARMA

AI, Forecasting, Insights and Analytics for Smarter Decisions in Pharma

BIOPROCESSING

Bioreactors and Cell Culture Media: A Practical Comparison for Upstream Bioprocessing

Latest News.

9th October, 2026

01. Shift Bioscience says better benchmarking could make AI “virtual cells” more useful for finding ageing drug targets

A new Nature Biotechnology paper argues that some genetic perturbation models were judged with poorly calibrated metrics, and the Cambridge company plans to use its fix to screen for rejuvenation and fibrosis targets.

26th September, 2026

02. Big Picture Bio launches with £2.2m to develop AI-designed cancer combination therapies

London biotech Big Picture Bio launches with £2.2m to develop AI-designed cancer combination therapies using a generative world model and wet-lab validation.

24th September, 2026

03. BIOPLUS-INTERPHEX KOREA 2026 to Showcase Global Biotech Innovation, with Canada Named Country of Honor

BIOPLUS-INTERPHEX KOREA 2026 (BIX 2026), Korea’s largest biotechnology and pharmaceutical convention, will take place at COEX in Seoul from October 28–30.

18th September, 2026

04. Andelyn reaches commercial manufacturing milestone following FDA approval of Fayuvi

Andelyn Biosciences has reached a commercial manufacturing milestone following the U.S. Food and Drug Administration’s (FDA) approval of Ultragenyx Pharmaceutical’s Fayuvi™ gene therapy for Sanfilippo syndrome type A.